Recurring kits carry a slower instrument cycle
- About 90% of sales come from consumables and related revenue, which makes results steadier than a pure equipment seller.
- QuantiFERON returned to growth in 2026, offsetting a drop in U.S. immigration testing demand.
- QuantiFERON, QIAstat-Dx, QIAcuity, and QIAGEN Digital Insights remain the main growth pillars.
- The company is placing its new automated systems with customers and expanding QIAstat-Dx into bloodstream infection testing.
- The CEO transition, weak China demand, and cautious instrument spending keep this from being a clean growth story.
Consumables are doing the heavy lifting
Qiagen's best trait is that most of its sales repeat. Labs buy its kits, reagents, and related products again and again after they adopt a workflow. Management said these recurring revenues are about 90% of total sales, which helps protect the business when customers delay big equipment buys.
That mix is showing up in margins and resilience. The QuantiFERON testing franchise recently returned to growth, which successfully offset a major decline in U.S. immigration testing. New automated systems like QIAsymphony Connect are also reaching customers.
The bear case is not broken, however. Instrument demand is still weak because labs are careful with capital spending. QIAGEN Digital Insights is moving more pharma customers to SaaS subscriptions, which can hold back near-term reported revenue.
The next year is mostly about execution. Investors need to watch who becomes the next CEO, whether 2028 margin goals stay realistic, and if QIAstat-Dx wins FDA approval for its new bloodstream panels by the end of 2026.
Razors, blades, and lab software
Qiagen follows a razor and blade model. The instrument is the razor. The test kits, sample prep products, reagents, and related consumables are the blades. That is why the company can still earn good margins when instrument sales are soft.
The company also sells bioinformatics through QIAGEN Digital Insights. Bioinformatics means software that helps scientists read and use biology data. This unit is moving pharma customers from longer license deals to SaaS, which means software sold as a subscription.
Qiagen sits in the middle of precision medicine. Drug companies, research labs, hospitals, and liquid biopsy developers use its tools to prepare samples, detect disease markers, and turn raw biology into usable answers.
Capital return is part of the story. Qiagen completed a $500 million share repurchase in January 2026 and recently added an annual cash dividend. That helps shareholders, but it does not remove the need for steady organic growth.
The products Finn watches
QuantiFERON
QuantiFERON is Qiagen's latent tuberculosis testing franchise. It recently returned to growth by finding broad demand that offset lower immigration testing.
QIAstat-Dx
QIAstat-Dx is used for syndromic testing, which checks for many possible causes of illness in one run. The menu recently added bloodstream infection panels in Europe.
QIAcuity
QIAcuity is Qiagen's digital PCR platform, a precise way to count DNA or RNA targets. The system expanded multiplexing from 5 to 12 targets per sample.
QIAGEN Digital Insights
QIAGEN Digital Insights sells bioinformatics tools to researchers and pharma customers. The move to SaaS can pressure near-term revenue, but it should make the business more recurring over time.
Sample technologies and automation
Sample prep is a core part of the workflow. QIAsymphony Connect and QIAsprint Connect are now placing with customers, with QIAmini expected in fall 2026.
Parse Biosciences
Parse Biosciences extends Qiagen into single-cell analysis, a field that studies one cell at a time. The deal closed in December 2025.
Mostly repeat-use products
This mix reflects management's 2025 and 2026 commentary that recurring revenues are about 90% of sales. Instruments remain more exposed to cautious lab capital spending.
What could go wrong
Instrument freeze lasts longer
Medium impact · High oddsQiagen's consumables are steady, but weak instrument placements can slow future pull-through. If labs keep delaying capital purchases, the installed base may grow more slowly than planned.
CEO handoff disrupts execution
High impact · Medium oddsThierry Bernard's planned exit adds risk at an important time. A new CEO will have to protect margin gains, finish the Parse integration, and keep the 2028 targets credible.
Tariffs and currency pressure margins
Medium impact · Medium oddsQiagen expanded margins in 2025 despite tariffs, but management has already flagged tariff and currency pressure. These external factors can quickly erase operational efficiency gains.
China stays weak
Low impact · High oddsChina is no longer a large part of the company, at less than 5% of sales. Still, high-teens CER declines show the market remains a drag and can hurt regional growth.
QDI SaaS shift masks demand
Medium impact · Medium oddsMoving QIAGEN Digital Insights customers to SaaS can reduce near-term reported revenue because subscription revenue is recognized over time. That is healthy if retention stays strong, but harmful if customers use the shift to leave.
In one breath
What does Qiagen do?
Qiagen makes tools that help labs move from a biological sample to a useful result. Its products include sample prep kits, molecular tests, diagnostic systems, digital PCR tools, and bioinformatics software.
Why does Qiagen have so much recurring revenue?
Many customers need to keep buying kits, reagents, and related consumables after they set up a Qiagen workflow. Management says these recurring revenues are about 90% of total sales.
What is the main bull case for QGEN stock?
The bull case is that recurring consumables keep growing and margins keep expanding. QuantiFERON is growing again, and new automation systems could add growth if execution stays on track.
What is the main risk for Qiagen?
The biggest near-term risk is execution during a CEO transition while instrument spending remains weak. Tariffs, currency, and the QDI SaaS shift add more pressure.
